Basel, April 5, 2017
INOFEA AG ANNOUNCES CLOSING OF ITS SERIES A+ ROUND WELL ABOVE TARGET.
This week, INOFEA successfully closed its financing round with contributions from returning as well as new private investors.
CEO Dr. Yves Dudal states: ”I am thrilled by the great support from our investors and the acceptance of our business model. We will use these funds to progress into a product based company by continuously growing the sales of empowered enzymes, and also explore the benefits of the platform for therapeutic enzymes in high medical need areas”.
The company was founded in 2014 in Basel as a spin-out from the School of Life Sciences, University of Applied Sciences and Arts, Northwestern Switzerland (FHNW).
INOFEA owns a highly innovative nanotechnology platform to shield sensitive enzymes and has positively demonstrated substantial benefits to customers in a number of biopharma-related applications.
Enzymes, or biocatalysts, are specialty proteins. Like antibodies to antigens, enzymes exhibit remarkable specificity for their substrate and naturally facilitate many chemical conversions.
INOFEA empowers enzymes. We have developed a unique and patented platform technology to fit enzymes to in vivo and process conditions. See how it works on this video.
We are developing a wealth of applications from this platform technology in both Pharma and Consumer Healthcare market segments. We can either formulate enzymes as drugs efficient in in vivo conditions (digestive health products, pancreatic enzyme products, personal care products, medical textiles, etc.) or improve industrial biocatalytic processes.